特发性膜性肾病免疫抑制治疗的最新进展
| 作者: |
1范耀冰,
1李艳艳,
1吴红赤
1 哈尔滨医科大学附属第一医院肾内科，哈尔滨 150001 |
| 通讯: |
吴红赤
Email: 2674724077@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.07.038 |
| 基金: | 黑龙江省教育厅科学技术研究项目(12541264)。 |
摘要
特发性膜性肾病(idiopathic membranous nephropathy，IMN)是肾病综合征最常见的病因之一，发病率逐年增加，30%~40%的IMN患者有持续性尿蛋白，并逐渐进展为终末期肾病，严重影响人们的健康。近几年各类新型免疫抑制剂投入临床使用，如新型单克隆抗体、蛋白酶体抑制剂、补体抑制剂，为IMN治疗提供了新的治疗方案。
关键词：
特发性膜性肾病；免疫抑制治疗；新型单克隆抗体；蛋白酶体抑制剂；补体抑制剂
Advanced progress in immunosuppressive therapy for idiopathic membranous nephropathy
CorrespondingAuthor: WU Hongchi Email: 2674724077@qq.com
DOI: 10.3978/j.issn.2095-6959.2021.07.038
Foundation: This work was supported by the Science and Technology Research Project of Heilongjiang Department of Education, China (12541264).
Abstract
Idiopathic membranous nephropathy (IMN) is one of the most common causes of nephrotic syndrome, and its incidence rate is increasing year by year. There are 30%–40% of IMN patients with persistent urinary protein which can develop to an end-stage renal disease, so it seriously affects people’s health. In recent years, various new immunosuppressive agents have been introduced into clinic, such as new monoclonal antibodies, proteasome inhibitors, complement inhibitor, has provided a new treatment regimen for IMN.
Keywords：
idiopathic membranous nephropathy; immunosuppressive therapy; new monoclonal antibodies; proteasome inhibitors; complement inhibitors